These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9099519)

  • 21. Predicting drug response and toxicity based on gene polymorphisms.
    Robert J; Morvan VL; Smith D; Pourquier P; Bonnet J
    Crit Rev Oncol Hematol; 2005 Jun; 54(3):171-96. PubMed ID: 15890268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The strategic use of genetic polymorphisms in carcinogen metabolizing enzyme for prevention of cancer].
    Ikawa S
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):454-9. PubMed ID: 9063483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of studies of selected metabolic polymorphisms and cancer.
    d'Errico A; Malats N; Vineis P; Boffetta P
    IARC Sci Publ; 1999; (148):323-93. PubMed ID: 10493265
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cytochromes P450: xenobiotic metabolism, regulation and clinical importance].
    Guéguen Y; Mouzat K; Ferrari L; Tissandie E; Lobaccaro JM; Batt AM; Paquet F; Voisin P; Aigueperse J; Gourmelon P; Souidi M
    Ann Biol Clin (Paris); 2006; 64(6):535-48. PubMed ID: 17162257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related disparities: influence of environmental factors.
    Olden K; White SL
    Med Clin North Am; 2005 Jul; 89(4):721-38. PubMed ID: 15925646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chapter 14. Ah receptor gene polymorphisms and human cancer susceptibility.
    Garte S; Sogawa K
    IARC Sci Publ; 1999; (148):149-57. PubMed ID: 10493256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
    Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
    Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility].
    González A; Ramírez V; Cuenca P; Sierra R
    Rev Biol Trop; 2004 Sep; 52(3):591-600. PubMed ID: 17361553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.
    Ginsberg G; Guyton K; Johns D; Schimek J; Angle K; Sonawane B
    Crit Rev Toxicol; 2010 Aug; 40(7):575-619. PubMed ID: 20662711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.
    Nebert DW; Ingelman-Sundberg M; Daly AK
    Drug Metab Rev; 1999 May; 31(2):467-87. PubMed ID: 10335448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical relevance of drug metabolism polymorphisms].
    Mikus G
    Ther Umsch; 2000 Sep; 57(9):573-8. PubMed ID: 11036438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of genetics and ethnicity in epilepsy management.
    Scheffer IE
    Acta Neurol Scand Suppl; 2005; 181():47-51. PubMed ID: 16238709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism.
    Banerjee BD; Kumar R; Thamineni KL; Shah H; Thakur GK; Sharma T
    Curr Drug Metab; 2019; 20(14):1103-1113. PubMed ID: 31933442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer.
    Neber DW; Roe AL
    Sci Total Environ; 2001 Jul; 274(1-3):93-102. PubMed ID: 11453308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition.
    Hines RN; Koukouritaki SB; Poch MT; Stephens MC
    Drug Metab Rev; 2008; 40(2):263-301. PubMed ID: 18464046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility.
    Gonzalez FJ
    Reprod Toxicol; 1997; 11(2-3):397-412. PubMed ID: 9100315
    [No Abstract]   [Full Text] [Related]  

  • 38. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes.
    Okey AB; Boutros PC; Harper PA
    Pharmacogenet Genomics; 2005 Jun; 15(6):371-9. PubMed ID: 15900209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genes encoding drug-metabolizing enzymes: possible role in human disease.
    Nebert DW
    Basic Life Sci; 1988; 43():45-64. PubMed ID: 2896496
    [No Abstract]   [Full Text] [Related]  

  • 40. The pharmacogenetics of chemical carcinogenesis.
    Idle JR; Armstrong M; Boddy AV; Boustead C; Cholerton S; Cooper J; Daly AK; Ellis J; Gregory W; Hadidi H
    Pharmacogenetics; 1992 Dec; 2(6):246-58. PubMed ID: 1306125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.